PERMANENT AWARD EVIDENCE
NHS England · published 17 Feb 2025. This page preserves the identifiers and current held fields for one Contracts Finder release; it is not an invoice, performance assessment or complete contract history.
8c603c5e-25d4-4ab4-8bb9-504458a54727-826898ocds-b5fd17-1266d8b9-9f94-4443-a0a5-21d13bc7faa8GB-CFS-156205A tender estimate and an award value answer different questions. Neither is treated as cash paid.
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 Offer reference number: CM/PHR/24/5680 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk
The current projection contains one award release, not a verified chain of planning, tender, award, contract and modification records. Dates are shown in source-field order and are not silently repaired.
A company profile appears only when this release carries a usable company number. Name-only suppliers remain name-only.
No supplier is named in this projection. That does not prove the notice had no supplier in every source version.
Published 17 Feb 2025 · held through the daily award projection · Open Government Licence v3.0.